Early trial aims to boost leukemia treatment with added immune drug
NCT ID NCT07392814
Summary
This early-stage study is testing whether adding the drug tocilizumab to a standard two-drug chemotherapy regimen is safe and tolerable for adults with acute myeloid leukemia (AML) who cannot receive intensive treatment. Researchers will gradually increase the dose of tocilizumab in small groups of up to 12 participants to find the safest amount. The goal is to see if this three-drug combination can better control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA ACUTE MYELOID - AML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU of Nantes
Nantes, 44000, France
Conditions
Explore the condition pages connected to this study.